| | Contents | |
| | | |
| |
| | | |
| | Volume 1 | |
| | Preface | V |
| | List of Contributors | XXXIX |
| Part A | Dendritic Cell Biology | 1 |
| 1 | Introduction to Some of the Issues and Mysteries Considered in this Book on Dendritic Cells Ralph M. Steinman | 3 |
| 1.1 | Dendritic Cells as a Distinct Hematopoietic Lineage | 3 |
| 1.1.1 | Chapters 1–16, the Life History of Dendritic Cells | 3 |
| 1.1.2 | Questions Concerning the Dendritic Cell Lineage | 4 |
| 1.2 | Control of Lymphocyte Responses by Dendritic Cells | 4 |
| 1.2.1 | Chapters 17–30, Initiation of Immunity | 4 |
| 1.2.2 | Questions Concerning Antigen Uptake, Processing and Presentation | 5 |
| 1.2.3 | Questions Concerning Dendritic Cell Maturation | 5 |
| 1.3 | Dendritic Cells in Disease Pathogenesis | 6 |
| 1.3.1 | Chapters 31–51, Dendritic Cells in Infectious and Other Diseases | 6 |
| 1.3.2 | Some Questions on the Roles of Dendritic Cells in Diseases | 7 |
| 1.4 | Dendritic Cells and the Design of Vaccines and New Therapies | 7 |
| 1.4.1 | Chapters 52–55, Dendritic Cells in Immunotherapy | 7 |
| 1.4.2 | Dendritic Cells and the Design of Vaccines against Infectious Diseases | 8 |
| | References | 9 |
| I | Dendritic Cell Development | 13 |
| 2 | Bone Marrow Progenitors of Dendritic and Natural Interferon-producing Cells Markus G. Manz | 13 |
| 2.1 | Hematopoietic Stem Cells and Successive Lineage-restricted Early Hematopoietic Progenitor Cells | 14 |
| 2.2 | Proposed Models for Dendritic and Natural Interferon-producing Cell Differentiation | 15 |
| 2.3 | Unexpected Redundancy in Dendritic and Natural Interferon-producing Cell Development from both Lymphoid and Myeloid Restricted Hematopoietic Progenitor Cells | 16 |
| 2.4 | Immediate Dendritic and Natural Interferon-producing Cell Precursors | 17 |
| 2.5 | Proposed ”flt3-license” Working Model for Steady-State Dendritic and Natural Interferon-producing Cell Development from Early Hematopoietic Progenitor Cells | 18 |
| 2.6 | Conclusions | 20 |
| | Acknowledgement | 21 |
| | References | 21 |
| 3 | Growth Factors Herbert Strobl, Barbara Platzer, Almut Jörgl, Sabine Taschner, Leonhard Heinz and Peter Reisner | 27 |
| 3.1 | Introduction | 27 |
| 3.2 | Short Description of Key Cytokines Involved in DC Development | 28 |
| 3.2.1 | Flt3 Ligand (FLT3L, FL) | 28 |
| 3.2.2 | GM-CSF (Granulocyte-macrophage Colony-stimulating Factor) | 29 |
| 3.2.3 | Interleukin 3 (IL-3) | 30 |
| 3.2.4 | Interleukin 4 (IL-4) | 30 |
| 3.2.5 | Interleukin-15 (IL-15) | 31 |
| 3.2.6 | TNFa (Tumor Necrosis Factor-alpha) | 31 |
| 3.2.7 | TGF-â1 (Transforming Growth Factor Beta-1) | 32 |
| 3.3 | Regulation of in vitro DC Hematopoiesis by Cooperating Cytokine Signals | 33 |
| 3.3.1 | Cytokines in the Induction and Amplification of CD1a+ Myeloid DC Subsets from Hematopoietic Progenitor Cells in vitro | 33 |
| 3.3.2 | Cytokines for Pre-expansion of Myeloid DC Progenitor Cells | 35 |
| 3.3.3 | Cytokine Combinations that Promote Myeloid DC Expansion Reciprocally Inhibit Plasmacytoid DC Development in Suspension Cultures | 36 |
| 3.3.4 | TGF- 1 and its Essential Co-signals for LC Differentiation from Hematopoietic Progenitor/Stem Cells | 39 |
| 3.3.5 | TGF- 1 Induces LC Differentiation from Monocyte Intermediates | 40 |
| 3.3.6 | Redundancy among Cytokine Signals Directing LC Differentiation from CD34+ Hematopoietic Progenitor Cells | 41 |
| 3.3.7 | TGF- 1-dependent LC Induction by in vivo Occurring Candidate Precursors | 41 |
| 3.3.8 | Cytokines Promoting the Generation of Monocyte-derived DC | 42 |
| 3.3.9 | Evidence for Cellular Heterogeneity of DC Arising from CD34+ Progenitors or Monocytes | 43 |
| 3.4 | Conclusions | 43 |
| | References | 44 |
| 4 | Transcription Factors: Deciphering the Transcription Factor Network of Dendritic Cell Development Thomas Hieronymus and Martin Zenke | 53 |
| 4.1 | Introduction | 53 |
| 4.2 | Ikaros | 54 |
| 4.3 | RelB | 55 |
| 4.4 | PU.1 | 56 |
| 4.5 | C/EBPa | 57 |
| 4.6 | Pax5 | 60 |
| 4.7 | IRF family | 60 |
| 4.8 | Id2 | 63 |
| 4.9 | Runx3 | 64 |
| 4.10 | Gfi1 | 64 |
| 4.11 | Concluding Remarks | 65 |
| | References | 66 |
| II | Sentinel Dendritic Cells in Nonlymphoid Organs | 73 |
| 5 | Epidermal Langerhans Cells Nikolaus Romani, Christoph H. Tripp, Gudrun Ratzinger, Christine Heufler, Franz Koch, Sem Saeland and Patrizia Stoitzner | 73 |
| 5.1 | Introduction and Definition | 73 |
| 5.2 | A Short Review of the History of Langerhans Cells | 73 |
| 5.3 | Characterization and Morphology of Langerhans Cells | 75 |
| 5.4 | Entry of Langerhans Cells into the Epidermis in Ontogeny and Adulthood | 76 |
| 5.4.1 | Entry of Langerhans Cells into the Epidermis during Ontogeny | 76 |
| 5.4.2 | Entry and Turnover of Langerhans Cells into the Adult Epidermis under Homeostatic Conditions | 77 |
| 5.4.3 | Entry and Turnover of Langerhans Cells into the Adult Epidermis under Inflammatory Conditions | 78 |
| 5.5 | Lineage of Langerhans Cells | 79 |
| 5.6 | Langerhans Cells in Lymphoid Organs | 80 |
| 5.7 | Langerhans Cells as a Paradigm for Dendritic Cell Function | 82 |
| 5.8 | The Changing of the Paradigm | 84 |
| 5.9 | Can Langerhans Cells Induce Immunity in vivo? | 85 |
| 5.10 | Can Langerhans Cells maintain Peripheral Tolerance in vivo? | 86 |
| 5.11 | Can Langerhans Cells be Applied in Immunotherapy? | 88 |
| 5.12 | Recent Methodical Advances Relevant for the Study of Langerhans Cells | 89 |
| | Acknowledgements | 90 |
| | References | 90 |
| 6 | Characterization of Dendritic Cells and other Antigen-presenting Cells in the Eye Joan Stein-Streilein | 101 |
| 6.1 | Introduction | 101 |
| 6.2 | APC in Various Regions of the Eye | 103 |
| 6.3 | DC/APC in the Retina | 103 |
| 6.4 | DC/APC in the Cornea | 105 |
| 6.5 | DC/APC in the Anterior Chamber | 105 |
| 6.6 | Mechanisms of ACAID Induction in the Spleen | 107 |
| 6.7 | The Role of the F4/80 Protein in ACAID | 109 |
| 6.8 | Therapeutic Potential of ACAID APC | 110 |
| 6.9 | Conclusions and Implications | 111 |
| | Acknowledgements | 111 |
| | Abbreviations | 112 |
| | References | 112 |
| 7 | Toll-like Receptors Hubertus Hochrein and Hermann Wagner | 119 |
| 7.1 | TLR and their Ligands | 119 |
| 7.2 | TLR Subfamilies | 121 |
| 7.3 | TLR and Dendritic Cell Subsets | 122 |
| 7.4 | TLR Signaling | 123 |
| 7.5 | What Determines the Outcome of the Immune Responses? | 124 |
| | References | 126 |
| 8 | C-type Lectins on Dendritic Cells: Antigen Receptors and Modulators of Immune Responses Yvette van Kooyk and Teunis B.H. Geijtenbeek | 129 |
| 8.1 | Introduction | 129 |
| 8.2 | DCs and Antigen Recognition Receptors | 130 |
| 8.3 | CLRs as Antigen Receptors for Homeostatic Control | 130 |
| 8.4 | CLRs as Adhesion Receptors | 131 |
| 8.5 | CLRs as Pathogen Receptors | 133 |
| 8.5.1 | HIV-1 as Prototypic Example for Virus-DC-SIGN Interactions | 133 |
| 8.6 | Glycan Modifications and Pathogen Recognition by DCs | 134 |
| 8.7 | CLRs as Signaling Receptors | 136 |
| 8.8 | CLRs and Recognition of Cancer | 137 |
| 8.9 | Concluding Remarks | 137 |
| | Abbreviations | 138 |
| | Acknowledgements | 138 |
| | References | 139 |
| 9 | Scavenger Receptors on Dendritic Cells Emma J. McKenzie, Subhankar Mukhopadhyay, Siamon Gordon and Luisa Martinez-Pomares | 141 |
| 9.1 | Introduction | 141 |
| 9.2 | Structure and Binding Properties of Mammalian Scavenger Receptors | 142 |
| 9.2.1 | Class A Scavenger Receptors | 143 |
| 9.2.1.1 | SR-A I,II and III (SR-A) | 143 |
| 9.2.1.2 | MARCO | 144 |
| 9.2.1.3 | SRCL-I | 146 |
| 9.2.2 | CD36 | 147 |
| 9.2.3 | LOX-1 | 148 |
| 9.2.4 | SREC-I | 149 |
| 9.2.5 | Other Members of the SR Family | 149 |
| 9.2.5.1 | CD68 | 149 |
| 9.2.5.2 | SR-B1, FEEL-1 and FEEL-2 | 150 |
| 9.3 | Role of Scavenger Receptors in Dendritic Cell Biology | 150 |
| 9.3.1 | SR and Antigen Internalization for Presentation to the Acquired Immune System | 151 |
| 9.3.1.1 | In vitro Generation of SR Ligands and its Effect in Immunogenicity | 151 |
| 9.3.1.2 | Crosspresentation of Ag Through Uptake of Apoptotic Cells | 152 |
| 9.3.1.3 | Crosspresentation of Ag Acquired through Live Cell Nibbling | 153 |
| 9.3.1.4 | Crosspresentation of Peptide-chaperone Complexes | 153 |
| 9.3.2 | Role of SR in the Modulation of Dendritic Cell Activation | 155 |
| 9.3.2.1 | Role of SR in Modulation of Dendritic Cell Phenotype in Response to Uptake of Apoptotic Cells | 155 |
| 9.3.2.2 | Role of SR in Modulation of Dendritic Cell Phenotype in Response to Uptake of Necrotic Cells | 155 |
| 9.3.2.3 | Cross-talk between SR and Toll-like Receptors | 156 |
| 9.4 | Concluding Remarks | 156 |
| | References | 157 |
| 10 | Production of the Long Pentraxin PTX3 by Myeloid Dendritic Cells: Linking Cellular and Humoral Innate Immunity Paola Allavena, Barbara Bottazzi, Andrea Doni, Luigina Romani, Cecilia Garlanda and Alberto Mantovani | 165 |
| 10.1 | Introduction | 165 |
| 10.2 | The Pentraxin Superfamily and the Prototypic Long PTX3: Molecules and Ligands | 165 |
| 10.3 | Myeloid DC as a Major Source of PTX3: Regulation of Production | 168 |
| 10.4 | Blood-circulating Myeloid, but not Plasmacytoid, DC Produce PTX3 | 169 |
| 10.5 | Role of PTX3 in Innate Immunity | 170 |
| 10.6 | Function of Antigen Presenting Cells in PTX3-deficient Mice | 170 |
| 10.7 | Conclusion | 171 |
| | References | 172 |
| 11 | Gene Profiling of Dendritic cells during Host–Pathogen Interactions Maria Foti, Francesca Granucci, Mattia Pelizzola, Norman Pavelka, Ottavio Beretta, Caterina Vizzardelli, Matteo Urbano, Ivan Zanoni, Giusy Capuano, Francesca Mingozzi, François Trottein, Toni Aebischer and Paola Ricciardi-Castagnoli | 175 |
| 11.1 | Dendritic Cells as Sentinels of the Immune System: Tissue-resident DC and Migratory DC | 175 |
| 11.2 | Study of the Complexity of the Immune System using Gene Profiling | 177 |
| 11.3 | Discovery of IL2 Production by DC using Global Technologies and the NK-DC Interplay | 179 |
| 11.4 | Profiling of Pathogens and Cells of the Innate Response: Mucosal Epithelial Cells, Phagocytic Cells (Neutrophils and Macrophages) | 180 |
| 11.5 | Dendritic Cells and Pathogen Interaction: Dendritic Cells as a Link between Innate and Acquired Immunity | 182 |
| 11.6 | Dendritic Cells as Sensors of Infection | 184 |
| 11.7 | DC Transcriptional Profile Induced by Pathogen Teaches the Dynamic of the Interactions: DC Transcriptome; Core and Specific Responses | 185 |
| 11.8 | DC and Shistosoma Mansoni Specific Signature | 186 |
| 11.9 | DC and Leishmania Mexicana: Molecular Profile of the Interaction | 190 |
| 11.10 | Conclusions | 192 |
| | References | 192 |
| III | Dendritic Cells in Secondary Lymphoid Organs | 199 |
| 12 | Dendritic Cell Subtypes Ken Shortman and Jóse A. Villadangos | 199 |
| 12.1 | Introduction | 199 |
| 12.2 | DC Surface Antigen Heterogeneity and the Recognition of DC Subtypes | 201 |
| 12.3 | DC Subtypes in Steady-state versus Infected Mice | 202 |
| 12.4 | Extraction and Enrichment of DC from Lymphoid Tissue | 203 |
| 12.5 | Plasmacytoid versus Conventional DC | 203 |
| 12.6 | Spleen DC Subtypes | 204 |
| 12.7 | Lymph Node DC Subtypes | 206 |
| 12.8 | Thymic DC | 208 |
| 12.9 | The Maturation State of Lymphoid Organ DC Subtypes | 209 |
| | | |
| 12.10 | Generation and Lifespan of DC Subtypes | 210 |
| 12.11 | Human DC Subtypes | 211 |
| 12.12 | Functional Differences between DC Subtypes | 212 |
| | References | 212 |
| IV | Circulating Dendritic Cells and their Precursors | 219 |
| 13 | pDC: From Plasmacytoid Dendritic Cell Precursors to Professional Type 1 Interferon-producing Cells Yong-Jun Liu, Holger Kanzler, Yui-Hsi Wang, Yi-Hong Wang, Michel Gilliet, Wei Cao and Tomoki Ito | 219 |
| 13.1 | Introduction | 219 |
| 13.1.1 | A Mysterious Cell Type with Plasmacytoid Morphology | 219 |
| 13.1.2 | A Mysterious Cell Type that has the Capacity to Produce Huge Amounts of Type 1 IFNs | 221 |
| 13.1.3 | From pDC to IPC | 221 |
| 13.1.4 | pDCs/IPCs in Mice, Rat, Pig, and Monkey | 222 |
| 13.2 | Isolation and Characterization of pDCs/IPCs | 222 |
| 13.2.1 | Isolation of Human pDCs/IPCs | 222 |
| 13.2.2 | Isolation of Mouse pDCs/IPCs | 222 |
| 13.2.3 | pDC/IPC Morphology | 223 |
| 13.2.4 | Surface Phenotype of pDCs/IPCs | 224 |
| 13.3 | pDC/IPC Development | 224 |
| 13.4 | Localization, Migration, and Lifespan of pDCs/IPCs | 227 |
| 13.5 | Innate Immune Response by pDCs/IPCs | 228 |
| 13.5.1 | pDCs/IPCs Selectively Express Intracellular TLR-7 and TLR-9 that Respectively Recognize Single-Stranded RNA and Double-Stranded DNA | 228 |
| 13.5.2 | pDCs/IPCs Are Professional Type 1 IFN-Producing Cells | 229 |
| 13.5.3 | pDCs/IPCs Rapidly Produce Large Amounts of IFN-a that Is Independent of Positive Feedback of IFN-â Through Type 1 IFN Receptors | 230 |
| 13.5.4 | TLR7/TLR9-mediated IFN-a production by pDCs/IPCs depends on Myd88-IRAK4-TRAF6-IRF-7 complexes | 231 |
| 13.5.5 | Human pDCs/IPCs Have a Limited Ability to Produce IL-12 | 231 |
| 13.5.6 | Myeloid DCs Are Specialized in Producing IL-12, but not Type 1 IFNs | 233 |
| 13.6 | Regulation of T-cell-mediated Immune Responses by pDCs/IPCs | 233 |
| 13.6.1 | pDC/IPC Differentiation to Mature DCs through Two Pathways | 233 |
| 13.6.2 | pDC-Derived DCs Induce Th1 by IFN- but not IL-12 | 235 |
| 13.6.3 | pDC-Derived DCs Induce Th2 through OX40L | 235 |
| 13.6.4 | pDC-Derived DCs and their Ability to Prime Naďve versus Memory T Cells | 235 |
| 13.6.5 | pDC-Derived DCs and Presentation of Endogenous and Exogenous Antigens | 235 |
| 13.6.6 | pDCs/IPCs and Cross-priming | 236 |
| 13.6.7 | pDCs/IPCs and Regulatory T Cells | 236 |
| 13.7 | pDCs/IPCs Regulate the Function of Conventional Myeloid DC by Type 1 IFN | 237 |
| 13.8 | Regulation of NK Cell Function by pDCs/IPCs | 238 |
| 13.9 | Regulation of B-cell Function by pDCs/IPCs | 239 |
| 13.10 | pDCs/IPCs and Human Diseases | 239 |
| 13.10.1 | HIV | 239 |
| 13.10.2 | Systemic Lupus Erythematosus (SLE) | 239 |
| 13.10.3 | Cancer | 240 |
| 13.11 | Conclusion | 240 |
| | Acknowledgments | 241 |
| | References | 241 |
| 14 | Monocyte subsets and their relation to DCs Brigitte Senechal, Darin Fogg, Gaelle Elain, and Frederic Geissmann | 253 |
| 14.1 | Monocytes and the Concept of the ”Mononuclear Phagocyte System” (MPS) | 254 |
| 14.1.1 | Blood Monocytes in the Mononuclear Phagocyte System | 254 |
| 14.1.2 | Plasticity of Monocytes as Studied in vitro and its Relevance to DC Differentiation in vivo | 256 |
| 14.1.3 | Contribution of Monocytes to Long-lived Resident Cells in Peripheral Tissues | 257 |
| 14.1.4 | Contribution of Monocytes to Short-lived Bone Marrow-derived Steady State Macrophages and DC | 258 |
| 14.1.5 | Evidence that Monocytes Contribute to Short-lived Migrating Dendritic Cells that Differentiate During Inflammation and Infection | 259 |
| 14.1.6 | Summary of the Respective Contribution of Monocytes to Individual Subsets of the MPS System | 260 |
| 14.2 | Molecular Determinants of Monocyte Differentiation | 260 |
| 14.3.2 | Monocyte Subsets | 262 |
| 14.3.3 | CCR2+ CX3CR1low ”Inflammatory” Monocytes | 264 |
| 14.3.4 | The Enigmatic CCR2- CX3CR1high Monocytes | 265 |
| 14.3.5 | Relationship Between CCR2+ CX3CR1low Monocytes and CCR2- CX3CR1high Monocytes | 266 |
| 14.3.6 | Additional Subsets of Monocytes? | 266 |
| 14.4 | Migration of Monocytes and Their Recruitment to Tissues | 267 |
| 14.4.1 | Monocyte Entry into the Target Tissues | 267 |
| 14.4.2 | Baseline Extravasation of Monocytes | 268 |
| 14.4.3 | Recruiment of Monocytes During Inflammation and Infection | 268 |
| 14.5 | Concluding remarks | 269 |
| | Acknowledgments | 270 |
| | References | 270 |
| V | Dendritic Cell Migration | 279 |
| 15 | Steady State Migration of Dendritic Cells in Lymph Gordon MacPherson, Simon Milling, Emma Turnbull and Ulf Yrlid | 279 |
| 15.1 | Introduction | 279 |
| 15.1.1 | Dendritic Cells | 279 |
| 15.1.2 | Why Study Lymph Dendritic Cells? | 280 |
| 15.1.3 | Lymphatic Terminology | 280 |
| 15.1.4 | Historical | 281 |
| 15.2 | Dendritic Cells in the Periphery | 281 |
| 15.2.1 | Constitutive Migration of Dendritic Cells from Peripheral Tissues | 281 |
| 15.2.2 | Exit of Dendritic Cells from Peripheral Tissues | 282 |
| 15.2.3 | Entry of Dendritic Cells into Peripheral Lymph | 282 |
| 15.3 | Lymph Dendritic Cells | 282 |
| 15.3.1 | Pseudo-afferent Lymph | 282 |
| 15.4 | Properties of Lymph Dendritic Cells in the Rat | 283 |
| 15.4.1 | Steady-state Output | 283 |
| 15.4.2 | Origin of Afferent Lymph Dendritic Cells | 283 |
| 15.4.3 | Steady-state Rat Lymph Dendritic Cells are ”Semi-mature” | 284 |
| 15.4.4 | Subsets of Rat Lymph Dendritic Cells | 284 |
| 15.4.5 | Migratory Fate of Lymph Dendritic Cells | 285 |
| 15.4.6 | Uptake and Transport of Apoptotic Cells by Intestinal Dendritic Cells | 286 |
| 15.5 | Dendritic Cells and B Cells | 286 |
| 15.6 | Dendritic Cells and the Pathogenesis of Transmissible Spongiform Encephalopathies (TSE) | 287 |
| 15.7 | Conclusions | 288 |
| | References | 288 |
| 16 | Multiple Pathways to Control DC Migration Karel Otero, Elena Riboldi, Annalisa Del Prete, Annunciata Vecchi, Fabio Facchetti, Alberto Mantovani and Silvano Sozzani | 295 |
| 16.1 | Dendritic Cells as Professional Migratory Cells | 295 |
| 16.2 | Role of Chemokines in the Recruitment of Myeloid and Plasmacytoid Dendritic Cells | 296 |
| 16.3 | Migration of Mature Dendritic Cells to Secondary Lymphoid Organs | 298 |
| 16.4 | Chemotactic Factors for Dendritic Cells: more than Chemokines | 301 |
| 16.5 | Tuning Dendritic Cell Migration by Nonchemotactic Signals | 303 |
| 16.6 | Concluding Remarks | 305 |
| | Acknowlegements | 305 |
| | References | 306 |
| VI | T-cell Activation and Co-stimulation | 313 |
| 17 | Antigen Processing and Presentation: CD1d and NKT cells Serani L.H. van Dommelen, Dale I. Godfrey and Mark J. Smyth | 313 |
| 17.1 | Introduction | 313 |
| 17.2 | CD1d and Antigen Presentation | 313 |
| 17.2.1 | The CD1d Molecule | 313 |
| 17.2.2 | Nature of CD1d and Glycolipid Recognition by TCR | 315 |
| 17.2.3 | Nature of CD1d-expressing APC | 316 |
| 17.3 | CD1d-restricted NKT Cells | 318 |
| 17.3.1 | Defining NKT Cells | 318 |
| 17.3.2 | Tissue Location and NKT Cell Subsets | 319 |
| 17.4 | Nature of the Antigens Presented by CD1d-expressing APC to NKT Cells | 319 |
| 17.4.1 | Self-ligands | 320 |
| 17.4.2 | Naturally-occurring Exogenous Ligands | 320 |
| 17.4.3 | Synthetic Ligands | 321 |
| 17.5 | Effector Functions of NKT Cells | 321 |
| 17.5.1 | Cytokine Secretion and Cytotoxicity of NKT Cells | 322 |
| | | |
| 17.5.2 | The Initial Cross-talk Between CD1d-expressing APC and NKT Cells | 322 |
| 17.5.3 | Functional Diversity of NKT Cell Responses | 323 |
| 17.5.4 | Modulation of Downstream Immune Responses by a-GalCer-activated Cells | 325 |
| 17.5.5 | Adjuvant-like Effect of NKT Cells on DC Mediated Antigen Presentation | 327 |
| 17.6 | Role of CD1d-restricted NKT Cells in Disease Models | 328 |
| 17.7 | Conclusions | 328 |
| | Acknowledgments | 328 |
| | References | 329 |
| 18 | The Role of Dendritic Cells in T-cell Activation and Differentiation Federica Sallusto and Antonio Lanzavecchia | 343 |
| 18.1 | Introduction | 343 |
| 18.2 | Requirements for Activation of Naďve T Lymphocytes | 343 |
| 18.2.1 | Co-stimulatory and Inhibitory Pathways | 345 |
| 18.2.2 | Differentiation to Effector T Cells | 345 |
| 18.3 | Dendritic Cell Maturation | 346 |
| 18.4 | T-cell Priming by Dendritic Cells | 347 |
| 18.4.1 | Priming of Th1 and Inflammatory T-cell Responses | 348 |
| 18.4.2 | Priming of Th2 Cells | 348 |
| 18.4.3 | Imprinting Tissue Homing Receptors | 349 |
| 18.4.4 | The Role of Plasmacytoid Dendritic Cells in T-cell Responses | 349 |
| 18.5 | Concluding Remarks | 350 |
| | References | 350 |
| 19 | Cytokines Produced by Dendritic Cells David F. Tough | 355 |
| 19.1 | Introduction | 355 |
| 19.2 | DC Cytokine Expression: A Few Caveats | 355 |
| 19.3 | Type I Interferon | 356 |
| 19.4 | IL-12, IL-23, IL-27 | 357 |
| 19.5 | IL-18 | 359 |
| 19.6 | IL-6 | 360 |
| 19.7 | IL-1 | 360 |
| 19.8 | TNF-a | 362 |
| 19.9 | Concluding Remarks | 363 |
| | Acknowledgement | 364 |
| | References | 364 |
| | | |
| |
| | Volume 2 | |
| VII | Th1 and Th2 Decision | 385 |
| 20 | The Plasticity of Dendritic Cells Populations in Promoting Th-cell Responses André Boonstra, Giorgio Trinchieri and Anne O’Garra | 385 |
| 20.1 | Effector Th-cell Populations | 385 |
| 20.2 | Factors Inducing the Development of Th1 or Th2 Cells | 386 |
| 20.2.1 | The Strength of DC–Th-cell Interaction | 387 |
| 20.2.2 | Co-stimulators | 388 |
| 20.2.3 | Genetic Background | 388 |
| 20.3 | Opposing Concepts: Pre-programmed versus Flexible DC Direct Th-cell Development | 388 |
| 20.3.1 | Mouse Dendritic Cell Populations in Directing Th-cell Development | 388 |
| 20.3.2 | Human Dendritic Cell Populations in Directing Th-cell Development | 390 |
| 20.4 | Differential TLR Expression by Distinct Dendritic Cell Populations | 392 |
| 20.4.1 | Modulation of TLR Expression | 392 |
| 20.5 | Modulation of IL-12p70 or IFN- Production | 393 |
| 20.6 | Factors Responsible for Driving Th2-cell Development | 395 |
| 20.7 | Modulation by Tissue Factors | 395 |
| 20.8 | Concluding Remarks | 396 |
| | References | 397 |
| 21 | Microbial Instruction of Dendritic Cells Esther C. de Jong, Hermelijn H. Smits, Eddy A. Wierenga and Martien L. Kapsenberg | 405 |
| 21.1 | Introduction | 405 |
| 21.2 | Effector Th1 and Th2 Cells and Regulatory T Cells | 405 |
| 21.3 | Dendritic Cells and Pattern Recognition Receptors | 406 |
| 21.4 | DC-derived Factors that Promote Th1, Th2 or Regulatory T-cell Responses | 408 |
| 21.4.1 | Th1 Cell-promoting Factors | 408 |
| 21.4.2 | Th2 Cell-promoting Factors | 410 |
| 21.4.3 | Regulatory T-cell-promoting Factors | 410 |
| 21.5 | TLR-mediated Activation of DC by Microbes and their Compounds | 411 |
| 21.5.1 | TLR2 | 411 |
| 21.5.2 | TLR3 | 412 |
| 21.5.3 | TLR4 | 412 |
| 21.5.4 | TLR5 | 413 |
| 21.5.5 | TLR7/8 | 413 |
| 21.5.6 | TLR9 | 413 |
| 21.5.7 | TLR10/11 | 414 |
| 21.6 | Th1 Cell-promoting DC | 414 |
| 21.7 | Th2 Cell-promoting DC | 415 |
| 21.8 | Regulatory T-cell-promoting DC | 415 |
| 21.9 | Indirect Priming of DC | 416 |
| 21.10 | Concluding Remarks | 417 |
| | References | 417 |
| VIII | CTL Priming and Crosspresentation | 427 |
| 22 | Crossprocessing and Crosspresentation Mojca koberne and Nina Bhardwaj | 427 |
| 22.1 | Introduction | 427 |
| 22.2 | Acquisition of Antigens for Crosspresentation | 428 |
| 22.2.1 | Cells that Crosspresent | 428 |
| 22.2.2 | Sources of Antigens and Receptors involved in Crosspresentation | 430 |
| 22.2.2.1 | Apoptotic Cells | 430 |
| 22.2.2.2 | Necrotic Cells | 432 |
| 22.2.2.3 | Heat-shock Proteins | 432 |
| 22.2.2.4 | Immune Complexes | 433 |
| 22.2.2.5 | Nibbling from Live Cells | 434 |
| 22.2.2.6 | Exosomes | 434 |
| 22.2.2.7 | TLR and MyD88 involvement in Crosspresentation | 435 |
| 22.3 | Mechanisms of Crossprocessing and Crosspresentation | 436 |
| 22.3.1 | Entry into the Classical Endocytic Pathway | 436 |
| 22.3.2 | Phagosome–endosome Compartment | 438 |
| 22.3.3 | A Special Mechanism for Soluble Antigens? | 439 |
| 22.3.4 | Tap Dependence and Endocytic Exchange Mechanism (Vacuolar Pathway) | 440 |
| 22.3.5 | Transfer of Peptides via Gap Junctions | 441 |
| 22.4 | Physiological Relevance of Crosspresentation | 442 |
| | Acknowledgements | 442 |
| | References | 443 |
| 23 | A Systems Biologist’s View of Dendritic Cell–Cytotoxic T Lymphocyte Interaction Burkhard Ludewig and Gennady Bocharov | 455 |
| 23.1 | Introduction | 455 |
| 23.2 | Deciphering the Systems Biologist’s Approach | 456 |
| 23.2.1 | Modularity and Protocols | 457 |
| 23.2.2 | Feedback Control | 458 |
| 23.2.3 | Redundancy | 460 |
| 23.2.4 | Structural Stability | 461 |
| 23.3 | From Systems Biology to DC–CTL Immunobiology | 461 |
| 23.3.1 | Dynamics of CTL Activation and Differentiation | 462 |
| 23.3.2 | Multiple Levels of Positive and Negative Feedback Control | 463 |
| 23.3.2.1 | Managing DC Recruitment and Antigen Translocation | 464 |
| 23.3.2.2 | Elimination of DCs by Effector CTL | 464 |
| 23.3.2.3 | Rapid Amplification of Signals through Molecular ”Ping–Pong” Interactions | 464 |
| 23.3.2.4 | Limiting the CTL ”Overshoot” through Feedforward Control | 465 |
| 23.3.3 | DC Subsets Provide Redundant Activating Signals | 466 |
| 23.3.4 | Tuning of Dendritic Cell Activation | 468 |
| 23.3.4.1 | Excitement through Pattern Recognition | 468 |
| 23.3.4.2 | DC Tuning and Tolerance to Self-antigens | 469 |
| 23.4 | Conclusions | 470 |
| | Acknowledgments | 470 |
| | References | 471 |
| IX | Dendritic Cells Cross-talk with Other Cell Types | 481 |
| 24 | Dendritic Cells and Natural Killer Cells Magali Terme and Laurence Zitvogel | 481 |
| 24.1 | Introduction on NK Cells | 481 |
| 24.2 | Activation of NK Cells by DC | 482 |
| 24.2.1 | NK-cell Activation and DC Subsets | 483 |
| 24.2.2 | Molecular Mechanisms of the DC-mediated NK-cell Activation | 483 |
| 24.3 | Reciprocal Interaction of DC and NK Cells | 484 |
| 24.3.1 | DC Maturation Induced by NK Cells | 485 |
| 24.3.2 | Lysis of DC by Activated NK Cells | 485 |
| 24.4 | Where do DC Meet NK Cells? | 486 |
| 24.4.1 | In Lymph Nodes | 486 |
| 24.4.2 | In the Periphery | 487 |
| 24.5 | DC/NK Cross-talk and T Lymphocytes | 487 |
| 24.5.1 | Bridging Innate and Adaptive Immunity | 487 |
| 24.5.2 | Modulation of the DC/NK-cell Cross-talk by CD4+CD25+ Regulatory T Cells and Conventional T Cells | 489 |
| 24.6 | The DC/NK-cell Cross-talk in Physiopathology | 490 |
| 24.6.1 | In Infectious Diseases | 490 |
| 24.6.1.1 | Viral Infections | 490 |
| 24.6.1.2 | Bacterial Infections | 491 |
| 24.6.2 | In Cancer | 491 |
| 24.7 | Concluding Remarks | 493 |
| | References | 494 |
| 25 | Intercellular Communication via Protein Transfer Marca H.M. Wauben | 499 |
| 25.1 | What are Exosomes, and Where do they Come From? | 499 |
| 25.2 | Which Cells are Targets for Exosomes, and how do Exosomes Interact with these Cells? | 500 |
| 25.3 | What is the Consequence of Exosome Binding or Uptake for the Target Cell? | 501 |
| 25.4 | What is the Physiological Role of Exosomes in the Immune System? | 502 |
| 25.5 | Cell–Cell Contact-dependent Transfer of Membrane Proteins | 504 |
| | | |
| 25.6 | How are Membrane Proteins Transferred Between Immune Cells, and What is their Fate? | 506 |
| 25.7 | What is the Physiological Role of Membrane Protein Swapping in the Immune System? | 508 |
| 25.8 | Concluding Remarks | 509 |
| | Abbreviations | 509 |
| | References | 510 |
| X | Tolerogenic Dendritic Cells | 517 |
| 26 | Differentiation Stages and Subsets of Tolerogenic Dendritic Cells Manfred B. Lutz | 517 |
| 26.1 | Introductory Remarks | 517 |
| 26.2 | Mechanisms of T-cell Tolerance Induction | 518 |
| 26.2.1 | Ignorance | 519 |
| 26.2.2 | Anergy | 519 |
| 26.2.3 | Deletion | 519 |
| 26.2.4 | Immune Deviation | 520 |
| 26.2.5 | The Concept of ”Immune Balance” | 520 |
| 26.2.6 | Regulation/suppression | 521 |
| 26.2.7 | Combinations | 521 |
| 26.3 | Tolerogenic DC Subsets in vivo | 522 |
| 26.3.1 | Thymic DC | 522 |
| 26.3.2 | DC in Lymph Nodes and Spleen | 523 |
| 26.3.3 | Migratory DC from Peripheral Organs | 523 |
| 26.3.4 | Plasmacytoid DC | 524 |
| 26.4 | DC Precursors | 524 |
| 26.5 | Immature DC | 525 |
| 26.5.1 | Tissue Resident DC | 525 |
| 26.5.2 | Induction of T-cell Anergy by Immature DC | 525 |
| 26.5.3 | Maturation Inhibitors | 526 |
| 26.5.4 | Maturation Resistance | 526 |
| 26.6 | Semi-mature DC | 528 |
| 26.6.1 | Steady-state Migratory DC | 530 |
| 26.7 | Fully Mature DC | 531 |
| | Acknowledgements | 531 |
| | Abbreviations | 531 |
| | References | 532 |
| 27 | Dendritic Cell Manipulation with Biological and Pharmacological Agents to Induce Regulatory T Cells Luciano Adorini and Giuseppe Penna | 545 |
| 27.1 | Introduction | 545 |
| 27.2 | Mechanisms Promoting Tolerogenic Dendritic Cells | 546 |
| 27.2.1 | Indoleamine 2,3-dioxygenase | 547 |
| 27.2.2 | Immunoglobulin-like Transcripts | 547 |
| 27.3 | Induction of Tolerogenic Dendritic Cells | 548 |
| 27.3.1 | Biological Agents Promoting Tolerogenic Dendritic Cells | 549 |
| 27.3.1.1 | IL-10 | 549 |
| 27.3.1.2 | TGF- | 550 |
| 27.3.1.3 | TNF- | 550 |
| 27.3.1.4 | G-CSF | 551 |
| 27.3.2 | Pharmacological Agents Promoting Tolerogenic Dendritic Cells | 551 |
| 27.4 | Induction of Tolerogenic Dendritic Cells by VDR Agonists | 553 |
| 27.4.1 | Tolerogenic Dendritic Cells Induced by VDR Agonists lead to enhancement of regulatory T cells | 555 |
| 27.4.2 | Upregulation of Inibitory Receptor Expression in Dendritic Cells by VDR agonists | 556 |
| 27.4.3 | Modulation of Chemokine Production by VDR Agonists can affect Recruitment of Effector T cells and CD4+CD25+ Ts cells to Inflammatory Sites | 557 |
| 27.5 | Common Features of Agents Leading to Induction of Tolerogenic DCs | 558 |
| 27.6 | Conclusions | 559 |
| | References | 560 |
| 28 | Surface Molecules Involved in the Induction of Tolerance by Dendritic Cells Laura C. Bonifaz | 569 |
| 28.1 | Introduction | 569 |
| 28.2 | Dendritic Cells and Central Tolerance | 570 |
| 28.3 | Dendritic Cells and Peripheral Tolerance | 570 |
| 28.4 | C-type Lectin Receptors | 571 |
| 28.4.1 | Advantages of DEC-205 as an Endocytic Receptor for Antigen Presentation | 572 |
| 28.4.2 | DEC-205: an Endocytic Receptor that Preserves the Steady State in the DC after the Capture of the Antigen | 573 |
| 28.5 | Induction of Peripheral Tolerance by Resting Dendritic Cells | 573 |
| 28.5.1 | The Same Dendritic Cells Could Operate in the Induction of Immunity | 574 |
| 28.5.2 | The Induction of Tolerance by Steady-state Dendritic Cells Promotes Avoidance of the Induction of Autoimmunity | 574 |
| 28.5.3 | Surface Molecules are Involved in Peripheral Tolerance Induction by Resting Dendritic Cells through DEC-205 | 575 |
| 28.5.4 | Additional Evidence Supports the Role of Resting DC in the Induction of Peripheral Tolerance | 575 |
| 28.6 | Surface Molecules Involved in the Induction of Peripheral Tolerance | 576 |
| 28.7 | Other Receptors Involved in the Induction of Tolerance that can Preserve the Resting of DC or Induce Negative Signaling | 577 |
| 28.7.1 | Integrins | 577 |
| 28.7.2 | Fc Receptors | 578 |
| 28.7.3 | Suppressor and Regulatory T Cells | 578 |
| 28.8 | Notch Ligands as Surface Molecules Involved in the Induction of Regulatory T Cells | 579 |
| 28.9 | ILT-3 and ILT-4: Two Inhibitory Molecules Involved in Tolerance Induction | 580 |
| 28.10 | Special DC for Tolerance? | 581 |
| 28.11 | Regulatory–tolerogenic DC | 582 |
| 28.12 | Concluding Remarks | 582 |
| | Acknowledgments | 583 |
| | References | 583 |
| 29 | Interaction Between Dendritic Cells and Apoptotic Cells Adriana T. Larregina and Adrian E. Morelli | 591 |
| 29.1 | Introduction | 591 |
| 29.2 | Dendritic Cells Phagocytose and Process Apoptotic Cells | 592 |
| 29.3 | The Phagocytic Synapse | 593 |
| 29.3.1 | Externalized Phosphatidylserine (PS) and Receptors for PS | 595 |
| 29.3.2 | Thrombospondin-1 (TSP-1), CD36 and the Integrins v 3 and v 5 | 596 |
| 29.3.3 | Complement Factors and Complement Receptors (CR) | 596 |
| 29.3.4 | Pentraxins | 598 |
| 29.3.5 | Milk-fat Globule Protein Epidermal Growth Factor 8 (MFG-E8)/lactadherin | 598 |
| 29.3.6 | Other Apoptotic Cell Recognition Signals | 599 |
| 29.4 | Redundant Receptors and Backup Mechanisms for Apoptotic Cell Clearance | 600 |
| 29.5 | Regulatory Effects of Early Apoptotic Cells on Dendritic Cells | 600 |
| 29.6 | Molecular Mechanisms of the Interaction between Dendritic Cells and Apoptotic Cells | 602 |
| 29.7 | Dendritic Cells, Apoptotic Cells and Peripheral Tolerance | 603 |
| 29.8 | The Potential Therapeutical Use of Apoptotic Cells for Peripheral Tolerance | 605 |
| 29.9 | Pathogens and Apoptotic Cell-like Mimicry | 607 |
| 29.10 | Dead Cells and the Delicate Balance between Immunity and Tolerance | 608 |
| 29.11 | Concluding Remarks | 610 |
| | Acknowledgements | 610 |
| | References | 611 |
| 30 | Pharmacologically Modified Dendritic Cells: A Route to Tolerance-associated Genes Kathleen F. Nolan, Stephen F. Yates, Alison M. Paterson, Paul J. Fairchild and Herman Waldmann | 619 |
| 30.1 | Dendritic Cells, Maturation and Tolerance | 619 |
| 30.2 | Gene Profiling | 622 |
| 30.2.1 | Gene Profiling Technologies | 623 |
| 30.2.2 | Serial Analysis of Gene Expression (SAGE) | 624 |
| 30.2.2.1 | SAGE Methodology | 625 |
| 30.2.2.2 | Handling Raw SAGE Data | 627 |
| 30.2.3 | Accumulation of a Comparative SAGE Resource for Identifying Tolerance-associated Genes | 628 |
| 30.2.3.1 | Relationship of Modulated DC Populations based on Gene Expression Patterns | 631 |
| 30.2.3.2 | Elucidation of ”Signatures” of Genes Associated with Tolerance | 632 |
| 30.2.3.3 | Identification of Novel Genes | 634 |
| 30.2.3.4 | AQ4 SAGE Library Comparisons Provide Insights to Biological Mechanism | 634 |
| 30.3 | Downstream Assessment of Tolerance Associated Candidate Genes | 636 |
| 30.3.1 | Simultaneous Assessment of Multiple Candidate Gene Expression Levels using a Custom ”Immunochip” | 636 |
| 30.3.2 | Assessing the Functional Relevance of Tolerance Candidates by Genetic Manipulation of DCs | 637 |
| 30.3.3 | Assessing the Functional Impact of Candidates in an in vivo Tolerance Model | 638 |
| 30.4 | Downstream Clinical Relevance | 638 |
| | References | 639 |
| Part B | Dendritic Cells in Disease | 649 |
| XI | Parasites | 651 |
| 31 | Malaria Britta C. Urban and Francis M. Ndungu | 651 |
| 31.1 | Introduction to Malaria | 651 |
| 31.2 | Antigenic Variation | 652 |
| 31.3 | Animal Models for Malaria | 653 |
| 31.4 | Acquired Immunity to Malaria | 653 |
| 31.4.1 | Immune Response to Liver Stages | 654 |
| 31.4.2 | Cellular Immunity to the Erythrocytic Stage | 654 |
| 31.4.3 | Humoral Immunity to the Erythrocytic Stage | 655 |
| 31.5 | Immune Recognition of iRBC | 656 |
| 31.5.1 | Toll-like Receptors | 656 |
| 31.5.2 | CD36 | 657 |
| 31.5.3 | Other Scavenger Receptors | 658 |
| 31.5.4 | Complement and Fc Receptors | 658 |
| 31.6 | Dendritic Cells in Malaria | 658 |
| 31.6.1 | DCs in Human Malaria | 658 |
| 31.6.2 | DCs in Rodent Malaria | 659 |
| 31.7 | Synopsis | 660 |
| | Acknowledgments | 662 |
| | References | 663 |
| 32 | Dendritic Cells in Leishmaniasis: Regulators of Immunity and Tools for New Immune Intervention Strategies Heidrun Moll | 669 |
| 32.1 | Introduction | 669 |
| 32.2 | Mechanisms Mediating Resistance or Susceptibility to Leishmaniasis | 670 |
| 32.2.1 | The Role of T Helper Cell Subsets | 671 |
| 32.2.2 | The Role of Regulatory T Cells | 672 |
| 32.3 | Dendritic Cell Interaction with Leishmania Parasites | 673 |
| 32.3.1 | Parasite Uptake by Dendritic Cells | 673 |
| 32.3.2 | Subcellular Location of Leishmania Parasites in Dendritic Cells | 674 |
| 32.3.3 | Dendritic Cell Subsets Involved in the Uptake of Leishmania | 675 |
| 32.3.4 | Dendritic Cells in Leishmania-infected Tissues | 676 |
| 32.4 | Dendritic Cell Migration and Induction of a Leishmania-specific Immune Response | 676 |
| 32.4.1 | The Role of Chemokines and Chemokine Receptors Expressed by Dendritic Cells | 677 |
| 32.4.2 | Transport and Presentation of L. major Antigen by Dendritic Cells | 678 |
| 32.4.3 | Parasite Persistence in Immune Hosts | 680 |
| 32.5 | Regulation of the Leishmania-specific Immune Response by Dendritic Cells | 680 |
| 32.5.1 | The Role of IL-12 Production by Dendritic Cells | 681 |
| 32.5.2 | Other Parameters that may Govern the Polarization of T Helper Cells | 682 |
| 32.6 | Parasite Evasion of Dendritic Cell Function | 683 |
| 32.7 | Dendritic Cells as Tools for Novel Immune Intervention Strategies Against Leishmaniasis | 685 |
| 32.7.1 | Dendritic Cell-based Vaccination and Immunotherapy | 685 |
| 32.7.2 | Parameters Determining the Efficacy of Dendritic Cell-based Immune Intervention Strategies | 686 |
| 32.8 | Conclusions and Perspectives | 687 |
| | References | 688 |
| 33 | Sentinel and Regulatory Functions of Dendritic Cells in the Immune Response to Toxoplasma gondii Alan Sher, Felix Yarovinsky, Romina Goldszmid, Julio Aliberti and Dragana Jankovic | 693 |
| 33.1 | Introduction | 693 |
| 33.2 | Activation of DC by T. gondii | 694 |
| 33.2.1 | Responsive DC Subpopulations | 694 |
| 33.2.2 | Host Receptors and Parasite Ligands Involved in Triggering of Murine DC | 696 |
| 33.2.3 | Activation of Human DC | 698 |
| 33.3 | Regulation of DC Activity | 699 |
| 33.4 | Role of DC in T. gondii-induced Immune Polarization | 700 |
| 33.5 | Mechanisms of Antigen Presentation to T Cells | 702 |
| 33.6 | Towards an Understanding of DC Function in vivo | 703 |
| | Acknowledgements | 704 |
| | References | 705 |
| 34 | Schistosoma Andrew S. MacDonald and Edward J. Pearce | 709 |
| 34.1 | Introduction | 709 |
| 34.2 | DC Response to Schistosome Ag | 710 |
| 34.3 | Th2 Induction by DC in Response to Schistosome Ag | 714 |
| 34.4 | DC During Schistosome Infection | 717 |
| 34.5 | Discussion | 718 |
| | Acknowledgements | 719 |
| | References | 719 |
| XII | Bacteria | 723 |
| 35 | Dendritic Cells and Immunity to Salmonella Mary Jo Wick | 723 |
| 35.1 | Introduction | 723 |
| 35.2 | Dendritic Cell Subsets, Short and Sweet | 724 |
| 35.3 | Dendritic Cells and Salmonella: Lessons from in vitro Studies | 724 |
| 35.3.1 | Bacterial Uptake and the Fate of Internalized Bacteria | 724 |
| 35.3.2 | Presentation of Salmonella Antigens by Dendritic Cells | 727 |
| 35.3.2.1 | Processing of Salmonella for Direct Presentation on MHC-II by Infected Dendritic Cells | 727 |
| 35.3.2.2 | Processing of Salmonella for Direct Presentation on MHC-I by Infected Dendritic Cells | 727 |
| 35.3.2.3 | Modulating of Antigen Presentation by Salmonella | 728 |
| 35.3.2.4 | Waste not, Want not: Dendritic Cells as Bystander Antigen-presenting Cells | 729 |
| 35.4 | Time to go to Work: Salmonella-induced Dendritic Cell Maturation | 730 |
| 35.5 | Murine Infection Models to Study Dendritic Cell Interaction with Salmonella in vivo | 733 |
| 35.5.1 | Salmonella Infection and Penetration of the Intestinal Epithelium | 733 |
| 35.5.2 | Dendritic Cell Take-up Salmonella in vivo | 734 |
| 35.5.3 | Getting the Game Started: Dendritic Cells Initiate Adaptive Immunity to Salmonella | 734 |
| 35.5.3.1 | Salmonella-induced Dendritic Cell Maturation During Infection | 734 |
| 35.5.3.2 | Presentation of Salmonella Antigens by Dendritic Cells in vivo | 736 |
| 35.6 | Concluding Remarks | 737 |
| | Acknowledgements | 737 |
| | References | 738 |
| 36 | Dendritic Cells in Tuberculosis Ulrich E. Schaible and Florian Winau | 745 |
| 36.1 | Introduction | 745 |
| 36.2 | Tuberculosis | 745 |
| 36.3 | Mycobacteria are Intracellular Pathogens | 747 |
| 36.4 | Dendritic Cells Present Antigens in Tuberculosis | 749 |
| 36.5 | Dendritic Cells are Regulatory Cells in Tuberculosis | 752 |
| 36.6 | Dendritic Cells and Cross-Priming | 753 |
| 36.7 | Mycobacteria Interfere with Antigen Presenting Cell Function | 755 |
| 36.8 | Conclusion | 756 |
| | Acknowledgement | 756 |
| | References | 756 |
| 37 | Dendritic Cell–Epithelial Cell Interactions in Response to Intestinal Bacteria Maria Rescigno | 759 |
| 37.1 | The Intestinal Epithelium and the Gut-associated Lymphoid Tissue (GALT) | 759 |
| 37.2 | Antigen Uptake in the Gut and DC Populations | 760 |
| 37.3 | Cross-talk between Bacteria and Epithelial Cells | 762 |
| 37.4 | Unique Functions of Mucosal DCs | 763 |
| 37.5 | Intestinal Immune Homeostasis is Regulated by the Cross-talk between ECs and DCs | 764 |
| 37.6 | Cross-talk between ECs and DCs in Bacterial Handling | 766 |
| 37.7 | Conclusions | 767 |
| | References | 767 |
| | | |
| |
| | Volume 3 | |
| XIII | Viruses | 773 |
| 38 | Sleeping with the Enemy: The Insidious Relationship between Dendritic Cells and Immunodeficiency Viruses L. Vachot, S.G. Turville, S. Trapp, S. Peretti, G. Morrow, I. Frank and M. Pope | 773 |
| 38.1 | Introduction | 773 |
| 38.1.1 | The Global AIDS Epidemic | 773 |
| 38.1.2 | Overview of Dendritic Cell Involvement in the Onset and Spread of HIV Infection | 774 |
| 38.1.3 | In vivo Evidence for DC Involvement in HIV Infection | 776 |
| 38.1.3.1 | Macaque Studies on Mucosal DCs and Infection | 776 |
| 38.1.3.2 | Changes in DC Biology in Immunodeficiency Virus Infection | 777 |
| 38.2 | Consequences of DC–HIV Interplay | 778 |
| 38.2.1 | HIV-binding Receptors Expressed by DCs | 778 |
| 38.2.2 | HIV Infection of DCs | 780 |
| 38.2.3 | Internalization of HIV Particles by DCs | 782 |
| 38.3 | DC-to-T-cell Transmission of Infectious Virus | 783 |
| 38.3.1 | Immunodeficiency Virus Replication in the DC–T Cell Milieu | 783 |
| 38.3.2 | Virus Movement across DC–T-cell Synapses | 784 |
| 38.3.3 | Two Phases of Virus Spread from DCs to T Cells | 786 |
| 38.4 | Inhibiting DC-driven Infection | 788 |
| 38.4.1 | Preventing direct HIV Interactions with DCs and DC–T-Cell Mixtures | 788 |
| 38.4.2 | DC-mediated HIV Transmission to T cells | 789 |
| 38.5 | Functional Modification of DCs by HIV Favors Infection over Immunity | 790 |
| 38.5.1 | Viral Factors Modify moDCs | 790 |
| 38.5.2 | Effects of Virus on Circulating DC Subsets | 791 |
| 38.5.3 | Virus-carrying Immature DCs Activate Substandard Virus-specific T-cell Responses | 792 |
| 38.6 | Implications for Vaccine and Microbicide Strategies | 793 |
| 38.6.1 | Blocking Mucosal Infection | 793 |
| 38.6.2 | Using DCs to Boost Immunity | 794 |
| 38.6.2.1 | DC-induced Primary Responses for Preventative HIV Vaccines | 795 |
| 38.6.2.2 | DC-based Therapeutic Control of Existing Immunodeficiency Virus Infection | 796 |
| 38.7 | Summary and Future Perspectives | 797 |
| | Acknowledgements | 797 |
| | References | 797 |
| 39 | Cytomegalovirus Infection of Dendritic Cells Brigitte Sénéchal and James W. Young | 813 |
| 39.1 | Introduction | 813 |
| 39.2 | HCMV Induces Immunosuppression | 813 |
| 39.3 | A Role for Dendritic Cells in the Pathology of CMV Infection | 814 |
| 39.4 | The Myeloid Lineage and Monocytes are Major Sites of HCMV Latency | 814 |
| 39.5 | Human Dendritic Cells are a Potential Target for HCMV | 815 |
| 39.6 | In vitro Evidence for HCMV Entry and Replication into Dendritic Cells | 816 |
| 39.7 | HCMV Impairs the Function of Immature Dendritic Cells | 817 |
| 39.8 | HCMV Impairs the Function of Mature Dendritic Cells | 818 |
| 39.9 | Langerhans-type Dendritic Cells are also Permissive to HCMV | 819 |
| 39.10 | Importance of Viral IL-10 in HCMV-induced Immunosuppression | 820 |
| 39.11 | CMV Infection of Dendritic Cells in the Mouse Model | 820 |
| 39.12 | Conclusion | 822 |
| | Acknowledgements | 823 |
| | References | 823 |
| 40 | Interactions of Hemorrhagic Fever Viruses with Dendritic Cells Stefan Pöhlmann | 829 |
| 40.1 | Introduction | 829 |
| 40.2 | Filoviruses | 830 |
| 40.2.1 | Pathology and Epidemiology | 830 |
| 40.2.2 | Replication | 831 |
| 40.2.3 | Tropism | 832 |
| 40.2.4 | Dendritic Cells are Major Targets of Ebolavirus | 832 |
| 40.2.5 | Filovirus Infection causes Aberrant Dendritic Cell Maturation | 833 |
| 40.2.6 | Filoviral Protein(s) Suppress Dendritic Cell Maturation | 834 |
| 40.3 | Dengue Virus (DEN) | 835 |
| 40.3.1 | Epidemiology and Pathology | 835 |
| 40.3.2 | Replication | 836 |
| 40.3.3 | Dengue Hemorrhagic Fever | 836 |
| 40.3.4 | Skin Dendritic Cells are Early Targets of Dengue Virus | 837 |
| 40.3.5 | Differential Effects of Dengue Virus on Infected and Bystander Dendritic Cells | 837 |
| 40.4 | Lassa Virus (LV) | 839 |
| 40.5 | Hantavirus (HTV) | 840 |
| 40.6 | Filoviruses and DEN Engage DC-SIGN, a Lectin Expressed on DCs | 841 |
| 40.6.1 | DC-SIGN – a Portal for Pathogens | 841 |
| 40.6.2 | Does DC-SIGN Promote Filovirus Infection in vivo? | 842 |
| 40.6.3 | DC-SIGNR – a DC-SIGN-related Attachment Factor that might Concentrate Filoviruses in Liver and Lymph Nodes | 844 |
| 40.6.4 | Dengue Virus Targets Dendritic Cells via DC-SIGN | 844 |
| 40.7 | Conclusions | 845 |
| | Acknowledgements | 846 |
| | Abbreviations | 846 |
| | References | 847 |
| 41 | Dendritic Cells in Measles Virus Pathogenesis Marion Abt, Nora Mueller and Sibylle Schneider-Schaulies | 855 |
| 41.1 | General Introduction | 855 |
| 41.2 | The Virus: Structure and Genotypes | 856 |
| 41.3 | The Role of Entry Receptors in Measles Virus Pathogenesis | 857 |
| 41.4 | Dendritic Cells in Measles Virus Pathogenesis | 859 |
| 41.4.1 | Measles Virus Interaction with Receptors on Dendritic Cells and Functional Consequences | 860 |
| 41.4.1.1 | Interaction with Surface Receptors | 860 |
| 41.4.1.2 | Functional Consequences of Measles Virus Surface Interaction with Dendritic Cells | 861 |
| 41.4.2 | Impact of Measles Virus on Dendritic Cell Viability and Maturation | 862 |
| 41.4.3 | Impact of Measles Virus on External Maturation/Stimulation Signals in Dendritic Cells | 863 |
| 41.4.4 | Impact of Dendritic Cells Measles Virus Infection on T-cell Viability, Activation and Expansion | 864 |
| 41.5 | Conclusions and Perspectives | 865 |
| | Acknowledgment | 867 |
| | Abbreviations | 868 |
| | References | 868 |
| 42 | Dendritic Cells and Herpes Simplex Virus Type 1 Alexander T. Prechtel and Alexander Steinkasserer | 875 |
| 42.1 | The Herpes Simplex Virus Type 1 | 875 |
| 42.1.1 | A Well-known Plaque for Centuries | 875 |
| 42.1.2 | The Role of Viral Immediate-early Proteins During the Conquest of the Cell | 875 |
| 42.1.3 | The Course of Herpes Simplex Virus Type 1 Infection and Replication | 878 |
| 42.2 | Herpes Simplex Virus meets Dendritic Cells | 879 |
| 42.2.1 | The Way into Dendritic Cells | 879 |
| 42.2.1.1 | Receptors and Ligands for Cell Entry | 879 |
| 42.2.1.2 | Infection of Different Dendritic Cell Populations by Herpes Simplex Virus Type 1 | 880 |
| 42.2.2 | Interference with Typical Functions of Dendritic Cells | 881 |
| 42.2.2.1 | Interference with Dendritic Cell Maturation | 881 |
| 42.2.2.2 | Interference with Dendritic Cell Migration | 882 |
| 42.2.2.3 | Interference with Dendritic-cell-mediated T-cell Stimulation | 884 |
| 42.3 | The Cell Surface Molecule CD83 | 885 |
| 42.3.1 | Characteristics of CD83 | 885 |
| 42.3.2 | Modulation of Dendritic Cell Function by Interference with CD83 mRNA Processing | 886 |
| 42.3.3 | The Soluble Extracellular Domain of CD83 and its Influence on T-cell Proliferation | 887 |
| 42.3.4 | The Function of Membrane-bound CD83 | 887 |
| 42.3.5 | Influence of CD83 on the T-cell Development in the Thymus | 888 |
| | Acknowledgements | 889 |
| | Abbreviations | 889 |
| | References | 889 |
| 43 | Epstein–Barr Virus Christian Münz | 897 |
| 43.1 | The Epstein–Barr Virus (EBV) | 897 |
| 43.2 | Immune Control of Epstein–Barr Virus | 898 |
| 43.3 | Stimulation of Lymphocyte Compartments Relevant to Epstein–Barr Virus Immune Control in vitro | 899 |
| 43.3.1 | Tonsillar Natural Killer Cell Activation by Dendritic Cells and its Possible Role in Epstein–Barr Virus Infection | 899 |
| 43.3.2 | Initiation of Epstein–Barr Virus-specific T-cell Immunity by Dendritic Cells | 900 |
| 43.4 | Evidence for Priming of Epstein–Barr Virus Immune Control by Dendritic Cells in vivo | 901 |
| 43.4.1 | Strong Th1 Polarization of CD4+ T-cell Responses to the Nuclear Antigen 1 of Epstein–Barr Virus (EBNA1) | 901 |
| 43.4.2 | Priming of Epstein–Barr Virus-specific Responses by Crosspresentation via Dendritic Cells Leads to Heterogeneous Affinity of T-cell Responses | 903 |
| 43.5 | Detection of Epstein–Barr Virus Infection by the Immune System | 903 |
| 43.6 | Immunotherapeutic use of Dendritic Cells against Epstein–Barr Virus | 904 |
| 43.7 | Summary | 905 |
| | References | 906 |
| XIV | Fungi | 915 |
| 44 | Dendritic Cells in Immunity and Vaccination against Fungi Luigina Romani and Paolo Puccetti | 915 |
| 44.1 | Introduction | 915 |
| 44.2 | Immunity to Fungi | 916 |
| 44.3 | Dendritic Cells at the Host/Fungi Interface | 917 |
| 44.3.1 | Fungal Recognition by Dendritic Cells and Receptor Cooperativity | 918 |
| 44.3.2 | Dendritic Cell Activation | 921 |
| 44.3.3 | Dendritic Cell Conditioning | 923 |
| 44.3.3.1 | Opsonins | 923 |
| 44.3.3.2 | Tryptophan Metabolic Pathway | 924 |
| 44.3.3.3 | T-cell Ligands | 925 |
| 44.3.3.4 | Other Cells | 925 |
| 44.4 | Dendritic Cells Translate Fungus-associated Information to Th1, Th2 and Treg Cells | 926 |
| 44.5 | Exploiting Dendritic Cells as Fungal Vaccines | 927 |
| 44.6 | Conclusions and Perspectives | 928 |
| | Acknowledgements | 929 |
| | Abbreviations | 929 |
| | References | 930 |
| XV | Autoimmunity | 935 |
| 45 | Dendritic Cells in Autoimmune Diseases Alexis Mathian, Sophie Koutouzov, Virginia Pascual, A. Karolina Palucka and Jacques Banchereau | 935 |
| 45.1 | Introduction | 935 |
| 45.2 | Dendritic Cells | 936 |
| 45.3 | Dendritic Cells and Tolerance | 936 |
| 45.3.1 | Central Tolerance | 936 |
| 45.3.2 | Dendritic Cells and the Control of Peripheral Tolerance | 938 |
| 45.4 | Dendritic Cell Activation and the Priming of Autoimmune Diseases | 939 |
| 45.4.1 | Autoimmunity through Bystander Activation of Dendritic Cells | 940 |
| 45.4.1.1 | Systemic Lupus Erythematosus as an IFN-a Driven Disease | 941 |
| 45.4.2 | Defective Downregulation of Activated Dendritic Cells | 942 |
| 45.4.3 | The Rise of ”Autoimmune-prone” Dendritic Cell Subsets | 942 |
| 45.5 | Dendritic Cells Migrate into Inflammatory Sites and Maintain a Vicious Circle | 945 |
| 45.6 | Dendritic Cells: Failure to Maintain Peripheral Tolerance | 946 |
| 45.7 | A Special Role for Plasmacytoid Dendritic Cells in Systemic Lupus Erythemathosus | 947 |
| 45.7.1 | Plasmacytoid Dendritic Cells as the Main Producer of Type I IFN in Systemic Lupus Erythemathosus | 948 |
| 45.7.2 | Plasmacytoid Dendritic Cells Induce Plasma Cell Differentiation | 948 |
| 45.8 | Dendritic Cells Fail to Delete Developing Autoreactive T Cells | 949 |
| 45.9 | Autoimmunity Through Cytokine-induced Dendritic Cell Activation | 949 |
| 45.10 | Different Cytokines Generate Different Dendritic Cells that may lead to Different Autoimmune Syndromes | 950 |
| 45.11 | Concluding Remarks | 951 |
| | Acknowledgements | 951 |
| | References | 952 |
| XVI | Transplantation | 967 |
| 46 | Role of Dendritic Cells in Graft Rejection and Graft-versus-host Disease Véronique Flamand and Michel Goldman | 967 |
| 46.1 | Alloantigen Presentation in Organ Transplantation | 967 |
| 46.1.1 | Pathways of Alloantigen Recognition | 967 |
| 46.1.1.1 | The Direct and Indirect Pathways | 967 |
| 46.1.1.2 | The Semi-direct Pathway | 969 |
| 46.1.2 | Sites of Alloantigen Presentation | 970 |
| 46.1.3 | Factors Inducing Dendritic Cell Maturation and Migration | 971 |
| 46.1.3.1 | Ischemia/reperfusion Injury | 971 |
| 46.1.3.2 | Links between Innate and Adaptive Immunity during Allograft Rejection | 972 |
| 46.2 | Alloantigen Presentation during Graft-versus-host Disease | 973 |
| 46.2.1 | Dual Impact of Alloreactive T Cells during Graft-versus-host Disease | 973 |
| 46.2.2 | Role of Host Dendritic Cells | 974 |
| 46.2.2.1 | Host Dendritic Cells in the Initiation and Effector Phases of Graft-versus-host Disease | 974 |
| 46.2.2.2 | Attempts to Eliminate Host Dendritic Cells | 975 |
| 46.2.2.3 | The Effects of Recipient Conditioning on Dendritic Cell Maturation | 975 |
| 46.2.2.4 | Reconstitution of Dendritic Cell ContentLAQ1L | 976 |
| 46.2.3 | Role of Donor Dendritic Cells | 977 |
| | Acknowledgements | 977 |
| | References | 978 |
| 47 | Dendritic Cells and Transplantation Tolerance Paul J. Fairchild, Stephen F. Yates and Herman Waldmann | 983 |
| 47.1 | The Expanding World of Transplantation | 983 |
| 47.2 | The Role of Dendritic Cells in Allograft Rejection | 985 |
| 47.2.1 | Direct Presentation of Alloantigen | 985 |
| 47.2.2 | Indirect Presentation of Alloantigen | 986 |
| 47.2.3 | The Semi-direct Pathway of Alloantigen Presentation | 987 |
| 47.2.4 | Pathways of Antigen Presentation during Cell Replacement Therapy | 988 |
| 47.3 | The Role of Dendritic Cells in Self-tolerance | 989 |
| 47.3.1 | A Cell Type with Two Persona | 989 |
| 47.3.2 | Dendritic Cell Subsets Devoted to Tolerance | 990 |
| 47.3.2.1 | Dendritic Cells Expressing CD8a | 990 |
| 47.3.2.2 | Plasmacytoid Dendritic Cells | 991 |
| 47.3.2.3 | ”Regulatory” Dendritic Cells | 993 |
| 47.3.3 | The Maturation Status of Dendritic Cells | 994 |
| 47.3.3.1 | Immature Dendritic Cells have an Enhanced Capacity to be Tolerogenic | 994 |
| 47.3.3.2 | Maturation of Dendritic Cells as a Trigger Point for Immunity | 996 |
| 47.4 | Exploitation of Dendritic Cells for Transplantation Tolerance | 997 |
| 47.4.1 | Central Deletion of Alloreactive T Cells | 997 |
| 47.4.2 | Peripheral Regulation of Alloreactive T Cells | 1000 |
| 47.4.3 | Reinforcing a Tolerogenic Phenotype by Genetic Modification | 1001 |
| 47.5 | Prospects for the Induction of Tolerance via the Indirect Pathway | 1002 |
| 47.6 | Immune Intervention in Cell Replacement Therapy | 1005 |
| 47.6.1 | Generation of Hematopoietic Stem Cells (HSC) for Mixed Chimerism | 1005 |
| 47.6.2 | Generation of Dendritic Cells for Tolerance Induction | 1006 |
| | References | 1008 |
| 48 | Dendritic Cells, Immune Regulation and Transplant Tolerance Giorgio Raimondi and Angus W. Thomson | 1017 |
| 48.1 | Introduction | 1017 |
| 48.2 | Dendritic Cells and Initiation of the Rejection Response | 1017 |
| 48.3 | Direct versus Indirect Pathways of Allorecognition | 1020 |
| 48.4 | Dendritic Cells and Tolerance Induction | 1021 |
| 48.5 | Mechanisms underlying Dendritic-cell-induced T-cell Tolerance | 1022 |
| 48.6 | Dendritic Cells and the Control of Organ Transplant Outcome | 1026 |
| 48.6.1 | Dendritic Cell Manipulation for Tolerance Induction: Specific Culture Conditions | 1027 |
| 48.6.2 | Dendritic Cell Manipulation for Tolerance Induction: Pharmacological Manipulation | 1027 |
| 48.6.3 | Dendritic Cell Manipulation for Tolerance Induction: Genetic Engineering | 1028 |
| 48.6.4 | Use of Specific Dendritic Cell Subsets for Tolerance Induction | 1029 |
| 48.6.5 | Dendritic Cell Therapy: Targeting the Indirect Pathway | 1031 |
| 48.6.6 | Dendritic Cells and the Treatment of Chronic Rejection | 1033 |
| 48.7 | Dendritic Cells and Cellular Markers of Transplant Tolerance | 1034 |
| 48.8 | Toward Clinical Use of Dendritic-cell-based Therapies for Tolerance Induction: Critical Considerations and Future Challenges | 1035 |
| 48.8.1 | Dendritic Cell–T Cell Interaction | 1035 |
| 48.8.2 | Dendritic Cells and Treg: a Complex Inter-relationship | 1036 |
| 48.8.3 | Fingerprints of ”Tolerogenic” Dendritic Cells | 1037 |
| 48.8.4 | Dendritic Cells at the Crossroads of the Immune System | 1037 |
| 48.9 | Conclusions | 1038 |
| | Acknowledgments | 1038 |
| | References | 1039 |
| XVII | Allergy, Asthma | 1047 |
| 49 | Nickel Presentation to T Cells in Contact Hypersensitivity H. U. Weltzien, K. Gamerdinger and H.-J. Thierse | 1047 |
| 49.1 | Introduction | 1047 |
| 49.2 | Molecular Basis of Nickel Presentation to Human T Cells | 1048 |
| 49.2.1 | CD4-positive T Cells | 1048 |
| 49.2.2 | CD8-positive T Cells and Non-HLA Restricted Nickel Presentation | 1051 |
| 49.3 | Nickel-Binding Proteins | 1051 |
| 49.3.1 | A Role for Carrier Proteins in Nickel Presentation | 1051 |
| 49.3.2 | Heatshock Proteins as Nickel Binders | 1052 |
| 49.4 | Concluding Remarks | 1053 |
| | References | 1055 |
| 50 | Dendritic Cells in Asthma Hamida Hammad and Bart N. Lambrecht | 1059 |
| 50.1 | Introduction | 1059 |
| 50.2 | Asthma as a Th2 Driven Disorder | 1059 |
| 50.3 | Lung Dendritic Cell Subsets | 1061 |
| 50.4 | Function of Lung Dendritic Cells in Primary Immune Responses to Inhaled Antigen and Sensitization to Inhaled Allergen | 1062 |
| 50.5 | Is Tolerance Induction in the Lung a Property of Specialized Dendritic Cell Subsets? | 1065 |
| | | |
| 50.6 | Accumulation of Mature Dendritic Cells in Ongoing Asthmatic Inflammation | 1066 |
| 50.7 | Direct Proof for a Functional Role for Dendritic Cells in Stimulating Effector Th2 Responses | 1068 |
| 50.8 | Determinants of Dendritic Cell Driven Th2 Responses in Asthma | 1069 |
| 50.9 | Dendritic Cells in Human Asthma | 1071 |
| 50.10 | Conclusion | 1072 |
| | References | 1073 |
| XVIII | Cancer | 1081 |
| 51 | Dendritic Cells in Human Cancer Casey A. Carlos and Olivera J. Finn | 1081 |
| 51.1 | Introduction | 1081 |
| 51.2 | Dendritic Cell Functions that are Important for Effective Immunity against Cancer | 1082 |
| 51.3 | Dendritic Cell Recognition of Malignant Changes in Tissues | 1083 |
| 51.4 | How Tumors Interfere with Normal Dendritic Cell Function | 1084 |
| 51.4.1 | Inhibition of Maturation and Differentiation | 1084 |
| 51.4.2 | Influence on Migration | 1085 |
| 51.4.3 | Suppression of Function | 1086 |
| 51.5 | Summary | 1087 |
| | References | 1088 |
| Part C | Therapeutical Applications of Dendritic Cells | 1093 |
| XIX | Cancer | 1095 |
| 52 | Dendritic Cell Subsets as Targets and Vectors for Vaccination Hideki Ueno, Joseph Fay, Jacques Banchereau and A. Karolina Palucka | 1095 |
| 52.1 | Introduction | 1095 |
| 52.2 | Cancer Vaccines | 1096 |
| 52.3 | Dendritic Cells | 1097 |
| 52.3.1 | Dendritic Cell Subsets | 1097 |
| 52.3.2 | Distinct Dendritic Cell Subsets Induce Distinct Types of Immune Response | 1099 |
| 52.3.3 | Dendritic Cells and Immune Tolerance | 1100 |
| 52.4 | Dendritic Cells as Cancer Vaccines | 1100 |
| 52.4.1 | Dendritic Cell Subsets | 1100 |
| 52.4.2 | Dendritic Cell Maturation | 1101 |
| 52.4.3 | Dendritic Cell Migration | 1102 |
| 52.4.4 | Antigen Loading | 1103 |
| 52.5 | Regulatory/suppressor Mechanisms | 1104 |
| 52.6 | Immunological and Clinical Efficacy | 1105 |
| 52.6.1 | Immunological Efficacy | 1105 |
| 52.6.2 | Clinical Efficacy | 1106 |
| 52.7 | Conclusions | 1107 |
| | Acknowledgements | 1107 |
| | References | 1107 |
| 53 | Renal Cell Carcinoma Martin Thurnher, Thomas Putz, Andrea Rahm, Hubert Gander, Reinhold Ramoner, Georg Bartsch, Lorenz Höltl and Claudia Falkensammer | 1117 |
| 53.1 | Dendritic Cells and Cancer Immunosurveillance | 1117 |
| 53.2 | Renal Cell Carcinoma | 1117 |
| 53.3 | Immunotherapy of Renal Cell Carcinoma | 1118 |
| 53.4 | Dendritic Cell-based Immunotherapy of Renal Cell Carcinoma | 1119 |
| 53.4.1 | The Two-step Culture System | 1119 |
| 53.4.2 | Generation of Clinical Grade Dendritic Cells | 1119 |
| 53.4.3 | Clinical Trials of Dendritic Cells in Renal Cell Carcinoma Patients | 1120 |
| 53.5 | Adjuvant Immunotherapy of Organ Confined Renal Cell Carcinoma after Partial or Radical Nephrectomy | 1122 |
| 53.6 | Patient Selection in Future Trials | 1123 |
| 53.7 | Adverse Effects – Quality of Life | 1123 |
| 53.8 | Concluding Remarks | 1124 |
| | Acknowledgements | 1124 |
| | References | 1124 |
| XX | Antigen Delivery | 1129 |
| 54 | Crosspresentation and Loading of Tumor Antigens for Dendritic Cell Vaccination against Cancer Madhav V. Dhodapkar | 1129 |
| 54.1 | Approaches to Antigen Loading for Dendritic-cell-mediated Immunotherapy | 1129 |
| 54.2 | Importance of Receptor-mediated Uptake to Crosspresentation | 1130 |
| 54.3 | Uptake of Dying Cells | 1131 |
| 54.4 | Uptake of Immune Complexes and Opsonized Pathogens and Tumor Cells | 1131 |
| 54.5 | Uptake of Heat Shock Protein–Peptide Complexes | 1132 |
| 54.6 | Exosomes as Sources of Multiple Tumor Antigens | 1133 |
| 54.7 | Role of C-type Lectin Receptors | 1133 |
| 54.8 | Other Routes of Antigen Entry for Crosspresentation | 1133 |
| 54.9 | Processing of the Antigenic Cargo | 1134 |
| 54.10 | Nature of the Antigenic Cargo | 1134 |
| 54.11 | Regulation of Crosspresentation during Dendritic Cell Maturation | 1135 |
| 54.12 | Role of Dendritic Cell Subsets in Crosspresentation | 1136 |
| 54.13 | Some Approaches to Improve Antigen Loading of Dendritic Cells for Clinical Vaccination | 1136 |
| 54.14 | Concluding Remarks | 1137 |
| | References | 1138 |
| 55 | Nucleic Acid Transfer Niels Schaft, Jan Dörrie and Dirk M. Nettelbeck | 1143 |
| 55.1 | General Introduction | 1143 |
| 55.2 | Antigen Delivery to DC by Adenoviral Gene Transfer | 1145 |
| 55.2.1 | Recombinant Adenovirus as Gene Transfer Vector | 1146 |
| 55.2.2 | Adenoviral Gene Transfer into Dendritic Cells in Vitro | 1149 |
| 55.2.3 | Adenoviral Antigen Delivery to DC for Ex Vivo Tumor Vaccination in Mouse Tumor Models | 1151 |
| 55.2.4 | Adenoviral Ag Delivery for HIV/SIV Vaccination in Monkeys | 1153 |
| 55.3 | Antigen Delivery to DC by Transfection of Nucleic Acids | 1154 |
| 55.3.1 | Passive Pulsing | 1155 |
| 55.3.2 | Electroporation | 1156 |
| 55.3.3 | Lipofection | 1159 |
| 55.4 | Concluding Remarks | 1160 |
| | References | 1161 |
| | Subject Index | 1173 |